Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
University of Maryland Dental School, Baltimore, Maryland, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico
Centre Hospitalier Universitaire de Montréal: Hôpital Notre-Dame, Montreal, Quebec, Canada
Mood Disorders Research Program and Clinic - UT Southwestern Medical Center, Dallas, Texas, United States
Shanghai Mental Health Center, Shanghai, Shanghai, China
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States
Women's Health Concerns Clinic, Hamilton, Ontario, Canada
Houston AIDS Research Team CRS, Houston, Texas, United States
Ucsd, Avrc Crs, San Diego, California, United States
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.